This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Last fall, private equity and hedge fund investors were given a reprieve from the prospect of increased oversight of healthcare transactions when California Governor Gavin Newsom unexpectedly vetoed Assembly Bill 3129 (AB 3129). By: Husch Blackwell LLP
The Bank of England’s Financial Policy Committee (FPC) and the Prudential Regulation Authority (PRA) recently delivered a series of speeches1 raising their concerns about the evolution of private equity financing and the banking sector’s exposure to the private equity industry.
antitrust regulators, particularly the Federal Trade Commission, have been stepping up scrutiny of private equity investments in healthcare. On March 5, the FTC, along with the U.S. Department of Justice and the U.S.
Despite initial expectations for a strong rebound in M&A activity driven by pent-up demand, private equity managers saw a slower recovery in 2024 than initially expected, with improvement in the latter half of the year. By: Akin Gump Strauss Hauer & Feld LLP
All indications appear to point toward a robust market for health care mergers and acquisitions (M&A) in the coming year. Inflation finally appears to be easing. With that, we may continue to see interest rate cuts from the Federal Reserve.
Founders Future, a well-known VC firm in the French tech ecosystem, acquired an equity crowdfunding marketplace called Sowefund. Here’s an interesting move. While terms of the deal remain undisclosed, Sowefund has been profitable since 2022 with around 20 employees.
USAP”), and the private equity firm Welsh, Carson, Anderson & Stowe (“Welsh Carson”), which created USAP, executed a multi-year anticompetitive scheme to consolidate anesthesiology practices in Texas, drive up the price of anesthesia services provided to Texas patients and boost their own profits. Anesthesia Partners, Inc.
Private equity (PE) sponsors often provide incentives to founders, equity holders, employees, directors, and officers of portfolio companies in the form of rollover equity or incentive equity to align their interests with those of the sponsors. By: Goodwin
After a subdued 2023 during which it was challenging for private equity (PE) to raise debt financing as a result of elevated interest rates and a difficult syndicated lending market, 2024 featured a material shift in the global credit landscape. By: Akin Gump Strauss Hauer & Feld LLP
California’s Senate Appropriations Committee will hold a hearing on California’s private equity bill, AB 3129, on August 15, 2024. This proposed legislation would expand existing California Attorney General authority to include review and approval authority over most healthcare private equity transactions. By: BakerHostetler
The company's spyware, dubbed Graphite, is capable of hacking phones and stealing private communications. 2024 TechCrunch. All rights reserved. For personal use only.
California is looking to take the lead on regulating private equity deals in the health care space by introducing bill AB 3129, which requires private equity groups or hedge funds to receive the state attorney general’s approval before purchasing a health care entity. and may encourage other states to establish similar legislation.
USAP”) and its private equity sponsor, Welsh, Carson, Anderson & Stowe (“Welsh Carson”) alleging an anticompetitive scheme to consolidate anesthesiology practices in Texas through a series of systematic roll-ups; price setting arrangements; and a market allocation agreement to dominate the anesthesia market in Texas.
Private equity firms can breathe a sigh of relief after a federal judge dismissed claims that threatened to establish a precedent for holding private equity firms liable for certain actions by their portfolio companies. By: Troutman Pepper
Technology continued to be an industry of particular focus for private equity (PE) through 2024. Blackstones $16 billion acquisition of data center platform Airtrunk was the largest deal of Q3 2024, according to Ernst & Young data, and tech deals accounted for 40% of all private equity deployment by value in the third quarter.
private equity market. Read our latest insights into the U.S. We cover monthly deal activity and size, fundraising, exits, leveraged loans, and a look ahead. PE dealmaking had a slower start in 2025. YTD deal numbers through February were below those for the same period in the past five years. By: Ropes & Gray LLP
As we begin 2024, we have highlighted the issues and trends that private equity (PE) investors should consider when evaluating transactions in the healthcare sector. W ith various headwinds resulting in down volume in 2023, buyers and sellers alike find themselves asking whether 2024 will see a rebound in deal activity.
The year 2023 will be remembered as a challenging one for private equity (PE), with complexities to navigate on many fronts. Although overall transaction volume was significantly down, private equity funds still found. By: Akin Gump Strauss Hauer & Feld LLP
Traditionally, private equity firms were seen as benign investors from an antitrust perspective. This is changing. In the past 12 months, PE-funded acquisitions have faced progressively more rigorous scrutiny by antitrust authorities. By: Allen & Overy LLP
Ropes & Gray recently published a survey of trends in Private Equity mergers & acquisitions. One interesting development noted in the survey is the increasing use full equity backstops in PE deals.
Sluggish M&A and IPO markets have put the brakes on private equity exit activity across Europe, but as pressure builds to clear the backlog of unsold portfolio companies, firms are taking innovative approaches to selling businesses - Europes private equity firms have a large backlog of unsold portfolio companies sitting on their books, and the (..)
Private equity sponsors can exhale: A federal court recently stopped the Federal Trade Commission's (FTC) antitrust action that targeted private equity sponsor Welsh, Carson, Anderson & Stowe for the healthcare "roll-up" strategy of its anesthesia practice management portfolio company. The case, Federal Trade Commission v.
Private equity (PE) firms play a critical role in revitalizing struggling businesses by providing, among other things, financial support and operational expertise. PE transactions are often driven by a combination of strategic growth objectives and tax planning opportunities. By: Bennett Jones LLP
On August 31, the last day of its 2024 Legislative Session, the California Legislature approved Assembly Bill 3129 (Wood), which provides for notification to and review by the Attorney General of health care transactions involving private equity groups and hedge funds. Governor Newsom is expected to sign the legislation in September.
Venable's Private Equity Investment in Healthcare webinar series explores the unique issues and timely developments that shape deals within the industry. Investment in the healthcare industry requires careful consideration, as it involves numerous distinct areas of the law. By: Venable LLP
As private equity firms, sovereign wealth funds, and other investors seek new avenues for growth, the sports arena offers a promising and dynamic landscape. In recent years, the sports industry has become an increasingly attractive area for investment, driven by new opportunities, evolving regulations, and a growing global fan base.
The term “rollover equity” is frequently used in discussions about the sale of middle market companies (which often is described as meaning companies with enterprise values from $10 million to $1 billion[1]), but frequently is not well understood by people selling middle market companies (particularly founder or family-owned companies).
The California Legislature recently passed Assembly Bill 3129 (“AB 3129” or the “Bill”), which, if signed by California Governor Gavin Newsom, would increase oversight of healthcare entity transactions involving private equity investment. Governor Newsom has until September 30, 2024, to sign or veto the Bill. By: Arnall Golden Gregory LLP
Episode 12: Exploring Consolidation and Private Equity Investment in Physician Practice Management - In this episode of BRight Minds in Healthcare Delivery, host Eric Tower interviews Robert Aprill, a partner at Physician Growth Partners. Eric and Robert examine private equity (PE) investment in physician services, including various.
Private equity is squarely in the cross hairs of regulators; the Department of Justice Antitrust Division, the Federal Trade Commission, and the U.S. Department of Health and Human Services recently announced the launch of a joint inquiry into private equity ownership in the health care field. By: Ballard Spahr LLP
Financial Conduct Authority has published a final report commissioned from Europe Economics to evaluate the potential impacts of implementing a pre-trade equities consolidated tape in the U.K., together with an update responding to the findings of the report. By: A&O Shearman
The Massachusetts legislative session for 2024 has come to a close without the passage of a bill that would have targeted private equity in healthcare.
Launching a private equity fund is an exciting yet daunting endeavor; and a General Partner (GP) Advisory Board can be a critical asset in navigating the complexities. Thoughtfully designing and engaging a GP Advisory Board strengthens a private equity firms capabilities by adding external expertise to the firms internal resources.
As some packed the skis and headed to their favorite slopes this winter season, it is hard not to see the analogies to the healthcare private equity (PE) transaction market as we ring in the New Year. Much like the Northern Rockies, there should be plenty of dry powder to support a robust dealmaking environment in 2025.
Driven by a growing wave of enforcer skepticism toward further healthcare consolidation, some state legislatures have begun to propose “mini-HSR” laws explicitly targeting healthcare transactions involving private equity firms or sponsors. By: Morgan Lewis
a federal district court granted private equity firm Welsh, Carson, Anderson & Stowe's motion to dismiss it from the Federal Trade Commission's (FTC) lawsuit alleging an anticompetitive scheme to drive up the price of anesthesia services by orchestrating a decade-long "roll-up" strategy to consolidate anesthesiology practices in Texas.
Private equity investment in health care has grown significantly over the past two decades, and the US government is starting to pay attention. The False Claims Act (FCA) appears to be the first avenue of enforcement, but private equity firms should be prepared for state. By: K&L Gates LLP
The Federal Trade Commission’s (FTC) push against private equity roll-ups has hit a snag. Judge Hoyt found that the FTC had not adequately alleged that Welsh Carson “is violating” or “is about to violate” antitrust laws, as required under.
The California legislature has introduced a bill that would implement some of the same restrictions on private equity health care investments as last years AB 3129. By: Polsinelli
At the end of last year, Holland & Knight predicted that "the current enforcement environment will continue into 2024 and will focus heavily on the healthcare industry, along with private equity transactions or 'roll-ups.' 15, 2023.)
On January 14, 2025, the Department of Justice (DOJ) sued private equity giant KKR & Co. KKR) for numerous violations of antitrust law, alleging that KKR repeatedly violated its obligations to provide information on its acquisitions as required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act). By: Goodwin
According to EY’s Private Equity Pulse, Q2 2024 was the strongest quarter in two years, with 122 announced transactions at a valuation of $196 billion total enterprise value. This seems to be the case, as we see initial signs of an improving landscape after a stronger Q2. But the US PE market is. By: Woodruff Sawyer
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content